载脂表位抗原特异性免疫治疗抑制HLA转基因小鼠FVIII抑制物抗体生成
本研究在HLA-DR2转基因小鼠中鉴定出2个FVIII免疫优势肽并优化为载脂表位(apitopes),组合为ATX-F8-117。按剂量递增方案给药可促进对FVIII的T细胞耐受,并显著减少FVIII抑制物形成,提示肽基抗原特异性免疫治疗有望抑制和治疗血友病A患者的抑制物。
要点
- ATX-F8-117由2个优化的FVIII载脂表位组成,可结合常见HLA-DRB1等位变体。
- 在HLA-DR2转基因小鼠中按剂量递增给药促进T细胞耐受并显著减少FVIII抑制物。
- 肽基抗原特异性免疫治疗是抑制血友病A抑制物形成的潜在策略。
核心结论
- 肽基抗原特异性免疫治疗ATX-F8-117可促进对FVIII的T细胞耐受并显著减少FVIII抑制物形成。
研究设计与样本
- 在FVIII免疫的HLA-DRA*0101/DRB1*1501转基因(HLA-DR2tg)小鼠中鉴定并优化FVIII免疫优势肽。
- 用FVIII特异性T细胞杂交瘤克隆筛选修饰肽类似物,并将2个载脂表位组合为ATX-F8-117。
- 按剂量递增方案给予ATX-F8-117,评估T细胞耐受与FVIII抑制物形成。
主要发现
- 鉴定出2个FVIII免疫优势肽并优化为载脂表位。
- FVIII载脂表位具有混杂性,可结合常见人HLA-DRB1等位变体。
- ATX-F8-117促进HLA-DR2tg小鼠对FVIII的T细胞耐受。
- ATX-F8-117显著减少FVIII抑制物形成,并调节抗FVIII的T细胞和B细胞反应。
临床怎么用
- 为血友病A患者抑制物的抗原特异性免疫治疗提供临床前依据。
- 支持进一步开发靶向CD4+ T细胞的肽基耐受方案以抑制FVIII抑制物。
局限性
- 研究仅在小鼠模型中进行,尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia A (HA) is a blood clotting disorder that is caused by various genetic deficiencies in the factor VIII (FVIII)-encoding F8 gene. Patients receiving FVIII-replacement therapy are at risk for developing neutralizing antibodies (FVIII inhibitors), rendering the FVIII-replacement therapy ineffective. Immunological tolerance toward FVIII can be achieved through immune tolerance induction protocols in some patients, but this is a lengthy and costly desensitization program. Long-term eradication of inhibitors in patients with HA could be achieved by antigen-specific immunotherapy targeting CD4+ T-cells, because formation of FVIII inhibitors is T-cell dependent. Here, we report a peptide-based antigen-specific immunotherapy that is designed to specifically reestablish immune tolerance to FVIII through the development of antigen-processing-independent epitopes (apitopes). We identified 2 FVIII immunodominant peptides in immunized HLA-DRA*0101/DRB1*1501 transgenic (HLA-DR2tg) mice that were optimized for tolerogenicity. These modified peptide analogs were initially screened for recognition using FVIII-specific T-cell hybridoma clones from FVIII-immunized HLA-DR2tg mice. The FVIII apitopes were promiscuous and bound common human HLA-DRB1* allelic variants. The combination of these 2 FVIII apitopes (ATX-F8-117), administered according to a dose-escalation protocol, promoted T-cell tolerance toward FVIII in HLA-DR2tg mice. Furthermore, treatment with ATX-F8-117 significantly reduced FVIII inhibitor formation. ATX-F8-117 regulates anti-FVIII T-cell and B-cell responses, specifically the generation of FVIII inhibitors, revealing peptide-based antigen-specific immunotherapy as a promising approach to suppress and treat inhibitor formation in susceptible patients with HA.
引用
- Pletinckx K, Nicolson KS, Streeter HB, et al. Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice. Blood Adv. 2022. PMID: 34529764. doi:10.1182/bloodadvances.2021004451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。